Colchicine, Bromhexine, and Hymecromone as Part of COVID-19 Treatment-Cold, Warm, Hot

Abstract

The TMPRSS2 (Transmembrane Protease Serine Subtype 2) inhibitor bromhexine hydrochloride (BRH) and the NLRP3 inflammasome inhibitor colchicine have been studied in a number of clinical trials with contradictory results. We started the treatment of Covid-19 outpatients and inpatients with the standard colchicine doses and found no effect. BRH pills also did not give the expected result.

That is why, from May 2020 the colchicine doses in our treatment regimen were increased while BRH was given inhaled. Our more than 2 years of experience and unpublished results clearly indicate that the immediate administration of BRH by inhalation, in combination with higher doses of colchicine to outpatients virtually eliminates the risk of complications and hospital admission. Moreover, the triple combination of inhaled BRH, optimal doses of Colchicine and hymecromone are an excellent means of reducing the mortality between 4 and 5 times of inpatients with Covid-19. Starting treatment as early as possible is extremely important. BRH is effective in prophylaxis if given for a long time (e.g. a month), especially before and during the actual COVID-19 wave.

Importantly, all three drugs are cheap and readily available. Furthermore, bromhexine and hymecromone have practically no side effects.